Previous Close | 2.0600 |
Open | 2.0500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 92.50 |
Expire Date | 2025-01-17 |
Day's Range | 2.0500 - 2.2300 |
Contract Range | N/A |
Volume | |
Open Interest | 1.76k |
Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and raises full-year guidance.
FOSTER CITY, Calif., October 09, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2024 financial results and provide a business update.
FOSTER CITY, Calif., October 09, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presentations, reflecting Gilead’s commitment to helping address the evolving needs of a diverse range of people and com